The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer
Abstract
Purpose: Several preoperative prostate cancer nomograms have been developed that predict risk of progression using pretreatment prostate-specific antigen (PSA) level, clinical stage, and biopsy Gleason grade. We describe the development and performance of a new nomogram. The nomogram adds new markers to the standard clinical predictors that reflect the biologic behavior of prostate cancer: pretreatment plasma levels of interleukin-6 soluble receptor (IL6SR) and transforming growth factor beta 1 (TGF-β 1). Patients and Methods: Between November 7, 1994 and December 22, 1997, 714 patients with stage cT1c to cT3a prostate cancer and no prior therapy were treated with radical prostatectomy at the Methodist Hospital, Houston TX. Plasma levels of IL6SR and TGF-β 1 were measured in banked preoperative plasma. With these data, a nomogram was developed to predict the probability of PSA progression within 5 years of surgery. The nomogram was validated with bootstrapping to assess its discrimination and calibration performance. Results: In the multivariable Cox model, PSA (P = .004), IL6SR (P < .001), TGF-β 1 (P < .001), primary Gleason grade (P < .002), and secondary Gleason grade (P = .029) were associated with PSA progression, whereas clinical stage (P = .696) was not. The nomogram seemed to be well calibrated and had a bootstrap-corrected area under the receiver operating characteristic curve (ie, concordance index) of 0.83. For comparison, a nomogram that omitted IL6SR and TGF-β 1 achieved a concordance index of only 0.75. Conclusion: We found that pretreatment plasma levels of IL6SR and TGF-β 1 improved the ability to predict biochemical progression by a prognostically substantial margin. A nomogram including the pretreatment levels of these molecular markers, along with standard clinical markers, has been developed and internally validated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261
Cited by
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., DiBlasio, C. J., Reuther, A., Klein, E. A., & Kattan, M. W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.867 · Cited by 663
Self-citationStephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Self-citationKenfield, S. A., Stampfer, M. J., Giovannucci, E., & Chan, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5226 · Cited by 601
The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers
Tomlins, S. A., Rhodes, D. R., Yu, J., Varambally, S., Mehra, R., Perner, S., Demichelis, F., Helgeson, B. E., Laxman, B., Morris, D. S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.016 · Cited by 314
Self-citationShariat, S. F., Karakiewicz, P. I., Suardi, N., & Kattan, M. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4713 · Cited by 288
Self-citation
Metadata
- Authors
- Kattan, M. W., Shariat, S. F., Andrews, B., Zhu, K., Canto, E., Matsumoto, K., Muramoto, M., Scardino, P. T., Ohori, M., Wheeler, T. M., & Slawin, K. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-10-01
- Volume
- 21
- Issue
- 19
- Pages
- 3573-3579
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164904188
- Cited by
- 208
- References
- 1
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.